Podcasts about Cardiovascular Research

You are called to assess a pregnant woman who presents to your hospital complaining of shortness of breath. She is 36 weeks pregnant with twins and tells you she had been getting progressively short of breath over the last month but put it down to the physical effects of the twin pregnancy in her abdomen. However last night she couldn't get her breath lying flat, had to sleep sitting up on 3-4 pillows and feels that "it is much worse". On examination she has a respiratory rate of 24/min, SpO2 = 92%, HR 105/min, BP 95/45 and you can hear crepitations in both lung fields. Her initial blood tests come back showing a raised plasma BNP and a bedside ECHO is done by a helpful colleague - who says "subjectively her LV isn't contracting very well". Hi everyone, This week I sit down with Dr Faith Njue the most qualified person here in WA to discuss the rare but important disease - peripartum cardiomyopathy. (See Faith's Bio below). Join us in our wide ranging discussion which touches on the diagnostic challenges, demographics, proposed mechanisms and general principles involved in managing these complex patients. Thanks Faith for a great discussion! Dr Faith Njue - Bio Faith Njue graduated from the University of Western Australia and completed cardiology training in Perth. She undertook further subspeciality training in advanced heart failure/ heart transplantation at Fiona Stanley Hospital and the University of Ottawa Heart Institute in Canada. Thereafter, she undertook further fellowship in cardio-obstetrics at the John Radcliffe hospital in Oxford (UK). She has special interest in women's cardiovascular health, heart disease in pregnancy and heart failure. Faith runs the dedicated Western Cardiology cardio-obstetrics clinic, designed to support women at risk of or with pre-existing heart conditions, through preconception counselling, pregnancy and into the post-partum period. Cardio-obstetrics is an expanding subspecialty that focuses on prevention, early detection, and appropriate management of cardiovascular disease in pregnancy. She holds public consultant positions at Sir Charles Gairdner and Fiona Stanley hospitals. She is part of the Advanced heart Failure and Cardiac Transplant team at FSH. She is the cardiology clinical lead for High Risk pregnancy at FSH. References Anaesthesia and peripartum cardiomyopathy Chapman, K. Njue F, Rucklidge M. BJA Education, Volume 23, Issue 12, 464 - 472 Melanie Ricke-Hoch, Tobias J. Pfeffer, and Denise Hilfiker-Kleiner. Peripartumcardiomyopathy: basic mechanisms and hope for new therapies. Cardiovascular Research (2020) 116, 520–531. doi:10.1093/cvr/cvz252​ Bauersachs J, König T, van der Meer P, et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 2019 Jul;21(7):827-843. doi: 10.1002/ejhf.1493. Epub 2019 Jun 27. PMID: 31243866​ 2018 ESC Guidelines for the Management of Cardiovascular Disease During Pregnancy. European Heart Journal 2018. Vol 39;3165-3241​ Bromocriptine: Koenig T, Bauersachs J, Hilfiker-Kleiner D. Bromocriptine for the Treatment of Peripartum Cardiomyopathy. Card Fail Rev. 2018 May;4(1):46-49. doi: 10.15420/cfr.2018:2:2. PMID: 29892477; PMCID: PMC5971672 Hilfiker-Kleiner D, Haghikia A, Berliner D, Vogel-Claussen J, Schwab J, Franke A, Schwarzkopf M, Ehlermann P, Pfister R, Michels G, Westenfeld R, Stangl V, Kindermann I, Kühl U, Angermann CE, Schlitt A, Fischer D, Podewski E, Böhm M, Sliwa K, Bauersachs J. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J. 2017 Sep 14;38(35):2671-2679. doi: 10.1093/eurheartj/ehx355. PMID: 28934837; PMCID: PMC5837241.

This episode covers:  Cardiology this Week: A concise summary of recent studies Coronary sinus reducer: promise in refractory angina Best strategies to reach LDL cholesterol goals in high-risk patients Snapshots Host: Susanna Price Guests: Carlos Aguiar, Rasha Al-Lamee, J. Wouter Jukema, Steffen Petersen Want to watch that episode? Go to: https://esc365.escardio.org/event/1807 Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1807?resource=interview Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Rasha Al-Lamee has declared to have potential conflicts of interest to report: speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. J. Wouter Jukema has declared to have potential conflicts of interest to report: J. Wouter Jukema/his department has received research grants from and/or was speaker (CME accredited) meetings sponsored/supported by Abbott, Amarin, Amgen, Athera, Biotronik, Boston Scientific, Dalcor, Daiichi Sankyo, Edwards Lifesciences, GE Healthcare Johnson and Johnson, Lilly, Medtronic, Merck-Schering-Plough, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis, Shockwave Medical, the Netherlands Heart Foundation, CardioVascular Research the Netherlands (CVON), the Netherlands Heart Institute and the European Community Framework KP7 Programme. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Susanna Price Guest: J. Wouter Jukema Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1807?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/1807 Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. J. Wouter Jukema has declared to have potential conflicts of interest to report: J. Wouter Jukema/his department has received research grants from and/or was speaker (CME accredited) meetings sponsored/supported by Abbott, Amarin, Amgen, Athera, Biotronik, Boston Scientific, Dalcor, Daiichi Sankyo, Edwards Lifesciences, GE Healthcare Johnson and Johnson, Lilly, Medtronic, Merck-Schering-Plough, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis,Shockwave Medical, the Netherlands Heart Foundation, CardioVascular Research the Netherlands (CVON), the Netherlands Heart Institute and the European Community Framework KP7 Programme. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

ReferencesCancer Med. 2012 Oct; 1(2): 176–186.Stem Cells. 2007 Feb;25(2):500-10. Cardiovascular Research 2022., cvac159, Nature Metabolism 2019.volume 1, pages 937–946 Nature Cardiovascular Research 2023. volume 2, pages 425–437 Vivaldi, A 1715. Glorias.https://music.youtube.com/watch?v=RMHguvZPcqQ&si=qPFr541Aep0KHle2Kaukonen. 1969."Good Shepard" Jefferson Airplame Volunteers.lphttps://music.youtube.com/watch?v=XtrYVj5e3cs&si=KSmil31KJwmH_P11

Un nuovo studio internazionale coordinato dall’I.R.C.C.S. Neuromed, in collaborazione con l’Università Sapienza di Roma e la Vanderbilt University (USA) e pubblicato su Cardiovascular Research evidenzia il ruolo inedito delle cellule del sistema immunitario nella regolazione della pressione arteriosa. A Obiettivo Salute il commento della prof.ssa Daniela Carnevale, ordinario dell’Università Sapienza e responsabile del Laboratorio di Ricerca Neuro e Cardiovascolare dell’I.R.C.C.S. Neuromed, che ha coordinato lo studio.

In this episode, Deputy Editor Dr. Zamaneh Kassiri (University of Alberta) interviews authors Dr. Oliver H. Wearing (University of British Columbia), Dr. Naomi C. Chesler (University of California Irvine), Dr. Mitchel J. Colebank (University of South Carolina), Dr. Timothy A. Hacker (University of Wisconsin-Madison), Dr. John N. Lorenz (University of Cincinnati), and Dr. Christopher R. West (University of British Columbia) about their new Guidelines in Cardiovascular Research article. This must-read Guidelines article provides a thorough overview of ventricular pressure-volume (PV) measurements in the mouse heart. PV measurements are an invasive method for assessment of heart function, and if done correctly, can provide researchers with valuable information about heart hemodynamics and the relationship between changes in ventricular pressure and volume during a cardiac cycle. The authors discuss PV measurements as the gold standard for assessing cardiac in vivo function. How do PV measurements differ from, and provide a complement to, echocardiography measurements? Listen and find out more.   Oliver H. Wearing, Naomi C. Chesler, Mitchel J. Colebank, Timothy A. Hacker, John N. Lorenz, Jeremy A. Simpson, and Christopher R. West Guidelines for assessing ventricular pressure-volume relationships in rodents Am J Physiol Heart Circ Physiol, published January 2, 2025. DOI: 10.1152/ajpheart.00434.2024

This week's guest is one of the most highly respected Sports Cardiologists in the world and a sub 2:30 marathoner. He is the Head of the Heart, Exercise and Research Trials Lab at St Vincent's Institute and the Victor Chang Cardiovascular Research Institute, as well as being a Cardiologist and Head of Cardiovascular Research at St Vincent's Hospital Melbourne. He completed a PhD at St Vincent's and University of Melbourne and 4 years of post-doctoral research at the University Hospital of Leuven in Belgium. His research and clinical work focuses on the effect of exercise on the human heart. He has more than 300 peer-review publications and text-book chapters, serves on multiple international guideline statements and is regularly invited to present at all major international cardiology conferences. Patreon Link: https://www.patreon.com/insiderunningpodcast Opening and Closing Music is Undercover of my Skin by Benny Walker. www.bennywalkermusic.com Join the conversation at: https://www.facebook.com/insiderunningpodcast/ To donate and show your support for the show: https://www.paypal.com/cgi-bin/webscr?cmd=_s-xclick&hosted_button_id=9K9WQCZNA2KAN

Sometimes negative results can be just as interesting as positive ones. Nivetha Subramaniam, a student at McGill University, discusses her research regarding the potential cardiovascular risks from exposure to mixtures of arsenic and cadmium with co-hosts Anne Chappelle, PhD, and David Faulkner, PhD.About the GuestNivetha Kamalavannan Subramaniam is a PhD student at McGill University in Canada. She is the recipient of the McGill Dr. Morris Karmazyn and Dr. Margaret P. Moffat Fellowship in Cardiovascular Research. The title of her PhD thesis project is "The Pro-atherogenic Effects of Arsenic and Cadmium Mixtures."Ms. Subramaniam serves as the Graduate Student Representative for the SOT Metals Specialty Section, and in 2023, she received the second place prize from the SOT Metals Specialty Section Student Research Award Fund.Send SOT thoughts on the episodes, ideas for future topics, and more.

In our latest episode, Dr. Jeff Saucerman (University of Virginia) interviews authors Dr. Naomi Chesler (University of California, Irvine) and Dr. Mitchel Colebank (University of South Carolina) about their new Guidelines in Cardiovascular Research article on incorporating mechanistic modeling into the analysis of experimental and clinical data to identify possible mechanisms of (ab)normal cardiovascular physiology. The authors' goal is to provide a consensus document that identifies best practices for in silico computational modeling in cardiovascular research. These guidelines provide the necessary methods for mechanistic model development, model analysis, and formal model calibration using fundamentals from statistics. Colebank et al. outline rigorous practices for computational, mechanistic modeling in cardiovascular research and discuss its synergistic value to experimental and clinical data. Would you like to understand how to apply a cone of uncertainty to your experimental data? Listen now to find out more.   Mitchel J. Colebank, Pim A. Oomen, Colleen M. Witzenburg, Anna Grosberg, Daniel A. Beard, Dirk Husmeier, Mette S. Olufsen, and Naomi C. Chesler Guidelines for mechanistic modeling and analysis in cardiovascular research Am J Physiol Heart Circ Physiol, published August 6, 2024. DOI: 10.1152/ajpheart.00253.2024

Professor Robert Byrne, Professor of Cardiovascular Research at the Royal College of Surgeons of Ireland, reacts to new research indicating that some weight loss drugs can also help people live longer.

Thomas Diacovo, MD, is chief of the UPMC Newborn Medicine Program and director of Neonatal Cardiovascular Research at the Heart Institute. Dr. Diacovo discusses how he became interested in Thrombosis research, his journey to Pittsburgh, and his research testing new drugs for neonatal intensive care patients, particularly those with congenital heart disease who are at high risk for forming blood clots. Dr. Diacovo also credits the parents of our patients for the success of his clinical trials.

Prof. Stefan Neubauer and Dr. Thomas Nero discuss two recent papers on the utility of coronary inflammation imaging on CT coronary angiography with Fat Attenuation Index (FAI)FAI score.  The Orfan study demonstrated a 29 fold increased risk in CV event rates with low vs high FAI score and a 10 fold increased event rate in patients with elevated FAI score who have no coronary plaque. FAI score re-categorized 40% of patients in their follow-up studies. Prof. Neubauer is the head of the Division of Cardiovascular Medicine and Director of the Oxford Centre for Clinical Magnetic Resonance Research (OCMR) at the University of Oxford and Past President of the Society for Cardiovascular Magnetic Resonance (SCMR).  He co-authored two recently published landmark papers:Farina NH, Mehta NN, Teague HL, et al. Inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease: the ORFAN multicentre, longitudinal cohort study. Lancet. 2024;403(10392):1823-1835. doi:10.1016/S0140-6736(24)00596-8Farina, C. J., Davidson, M. H., Shah, P. K., Stark, C., Lu, W., Shirodaria, C., Wright, T., Antoniades, C. A., & Nilsson, J. (2024). Inhibition of oxidized low-density lipoprotein with orticumab inhibits coronary inflammation and reduces residual inflammatory risk in psoriasis: a pilot randomized, double-blind placebo-controlled trial. Cardiovascular Research, European Society of Cardiology, March 25, 2024.

Audio Summary by Dr Yuwen Chen

This episode of our podcast takes a deep dive into intermittent fasting and its effects on health. Joining the conversation is Ali Javaheri, MD, PhD, assistant professor of medicine from the Center for Cardiovascular Research at Washington University. Dr Javaheri explains what intermittent fasting does to the body and discusses the benefits and dangers of this eating plan in light of a recent viral study that found 8-hour time-restricted eating may relate to a higher risk of cardiovascular death. 

In our latest episode, Consulting Editor Dr. Kristine DeLeon-Pennell (Medical University of South Carolina) interviews fellow co-authors Dr. Charlotte Usselman (McGill University), Dr. Judy Regensteiner (University of Colorado Anschutz Medical Campus), Dr. Kerrie Moreau (University of Colorado Anschutz Medical Campus), Dr. Austin Robinson (Indiana University Bloomington), Dr. Jesse Moreira-Bouchard (Boston University), and Dr. Quin Denfeld (Oregon Health and Science University) about their recently published guidelines on the use of sex and gender in cardiovascular research. Until recently, the effects of sex and gender in cardiovascular research have been largely ignored in research design and reporting. The result is that women and gender diverse individuals have been understudied in basic and clinical research, leading to a lack of understanding of sex and gender in cardiovascular health and disease. The goal of these guidelines is to provide researchers with practical and actionable advice on best practices to include sex and gender considerations in study design, data collection, analysis, and interpretation. As Dr. Judy Regensteiner points out, “We have to make it doable. We can't just say, ‘Go do this.' We have to show people how to do it.” Ready to get started? Listen now to learn more.   Charlotte W. Usselman, Merry L. Lindsey, Austin T. Robinson, Beth A. Habecker, Chloe E. Taylor, W. David Merryman, Derek Kimmerly, Jeffrey R. Bender, Judith G. Regensteiner, Kerrie L. Moreau, Louise Pilote, Megan M. Wenner, Myles O'Brien, Timur O. Yarovinsky, Nina S. Stachenfeld, Nisha Charkoudian, Quin E. Denfeld, Jesse D. Moreira-Bouchard, W. Glen Pyle, and Kristine Y. DeLeon-Pennell Guidelines on the use of sex and gender in cardiovascular research Am J Physiol Heart Circ Physiol, published December 21, 2023. DOI: 10.1152/ajpheart.00535.2023

This month on Episode 55 of Discover CircRes, host Cynthia St. Hilaireaire highlights two original research articles featured in the December 8th issue of Circulation Research. This Episode also includes a discussion with Dr José Luis de la Pompa and Dr Luis Luna-Zurita from the National Center for Cardiovascular Research in Spain about their study, Cooperative Response to Endocardial NOTCH Reveals Interaction With Hippo Pathway.   Article highlights: Shi, et al. Nat10 Mediated ac4C in Cardiac Remodeling Knight, et al. CDK4 Oxidation Attenuates Cell Proliferation

References Sinatra, Frank. timeless. My Way. https://youtu.be/qQzdAsjWGPg?si=TcpVOHDikKyyQdmC Acta Neuropathol. 2023 Jun;145(6):749-772 Signal Transduction and Targeted Therapy 2022. volume 7, Article number: 175 Cardiovascular Research 2007. 74: 526 – 536 J Investig Med. 2023 Feb;71(2):113-123 --- Send in a voice message: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/message Support this podcast: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support

Atrial fibrillation (AFib) not only causes shortness of breath and palpitations but puts patients at increased risk of stroke. When medication or other treatments fail to relieve symptoms, cardiologists increasingly perform a catheter ablation procedure. A new study published in the Journal of the American College of Cardiology shows the procedure is successful in most patients, with few side effects. Joining me today to talk about AFib, medication treatments, cardiac ablation and the recent study is Peter R. Kowey, MD. Dr Kowey is a professor of medicine and clinical pharmacology at Sidney Kimmel Medical College at Thomas Jefferson University and the William Wikoff Smith Chair in Cardiovascular Research. In addition, Dr Kowey is the senior author of the study–Initial Findings From the National Cardiovascular Data Registry of Atrial Fibrillation Ablation Procedures Check out the video podcasts at Outbreak News TV on YouTube  

In honor of American Heart Month, we spoke with Dr. Michael Koren, Medical Director and CEO of ENCORE Research Group, as he shares his top tips for heart health – especially for busy professionals working in the clinical research industry. Dr. Koren also explores how cardiovascular research and treatment have progressed over the past several years as well as some exciting new learnings for this vital therapeutic area.

This year marks the 50th anniversary of the Bogalusa Heart Study. Started in 1973, this study looks at the impact of vascular and metabolic changes on health throughout the lifespan. And, it's one of the longest on-going health studies of a biracial, semi-rural southern community.  Director of the Tulane Center for Lifespan Epidemiology Research, Dr. Lydia Bazzano tells us about the profound impact this study has had on various fields of research over the last half century. This weekend, the American Red Cross of Louisiana will head to Baton Rouge for a day of installing free smoke alarms. WWNO's Karl Lengel speaks with Ed Bush, Executive Director, Capital West Chapter in the Louisiana Region for the American Red Cross, to learn more about this event and hear how to mitigate fire risks.  Late last year, the Environmental Protection Agency announced that 53 million dollars would go out to communities across the nation to monitor air pollution. One of those recipients is the Cherokee community in Pascagoula, Mississippi where community members there have been sounding the alarm for a decade. But as the Gulf States Newsroom's Danny McArthur reports, many are skeptical that the new testing will fix their problems. Today's episode of Louisiana Considered was hosted by Alana Schreiber. Our managing producer is Alana Schreiber and our digital editor is Katelyn Umholtz. Our engineers are Garrett Pittman and Aubry Procell.  You can listen to Louisiana Considered Monday through Friday at 12:00 and 7:30 pm. It's available on Spotify, Google Play, and wherever you get your podcasts.  Louisiana Considered wants to hear from you! Please fill out our pitch line to let us know what kinds of story ideas you have for our show. And while you're at it, fill out our listener survey! We want to keep bringing you the kinds of conversations you'd like to listen to. Louisiana Considered is made possible with support from our listeners. Thank you!See omnystudio.com/listener for privacy information.

Mucho se habla del azúcar y de la grasa y poco se habla de la sal y no por ello es más saludable, así que hablemos de sal.La sal en sí misma no es perjudicial, de hecho, es necesaria para nuestro organismo ya que está involucrada en múltiples funciones: nerviosa, de regulación… El problema viene cuando consumimos esa sal en exceso.Los alimentos ya contienen sal de forma intrínseca, es la sal propia de cada alimento. Pero es que además nosotros añadimos más sal, tanto a la hora de cocinar como a la hora de aderezar nuestros platos y es ahí donde viene el problema, si ese consumo de sal supera los 5 g al día.Esta es la cantidad máxima recomendada por la OMS, que nos dice que no debemos tomar más de 2 g de sodio al día, que es lo que equivale a esos 5 g de sal. Sin embargo el consumo medio en la población española está entre 9 y 12 gramos de sal al día. Ya os he explicado en otras ocasiones que la primera causa de muerte en España es por enfermedades cardiovasculares y tanto es así que se estima que cada año se podrían evitar 2,5 millones de defunciones si el consumo de sal a escala mundial se redujera al nivel recomendado. Te explico todo esto porque un nuevo estudio publicado en la Cardiovascular Research ha relacionado el consumo de sal no solo con la hipertensión y enfermedad cardiovascular, sino también con el aumento del cortisol. Este estudio, que traduciendo su título sería algo como "El alto consumo de sal activa el eje hipotalámico-pituitario-suprarrenal, amplifica la respuesta al estrés y altera la exposición tisular a los glucocorticoides en ratones" concluye que los animales expuestos a un mayor consumo de sal tenían niveles más altos de glucocorticoides (cortisol en humanos, corticosterona en ratones), que son hormonas con importantes funciones cardiovasculares, cognitivas y metabólicas y que se liberan como respuesta del organismo a situaciones estresantes o amenazas. Y, aunque nunca podemos trasladar los estudios de ratones a los humanos, la asociación encontrada en esta investigación va en la línea de artículos anteriores que reflejaban una relación entre el consumo de sal y la excreción de cortisol en la orina. En humanos sabemos que el exceso de sal produce más glucocorticoides y aumenta la excreción de los mismos.¿Cuál es pues el tratamiento?El tratamiento dietético especifico de la hipertensión es la dieta DASH, que te hablé de ella en el episodio 246 de este podcast y en la clase 5 del curso como perder peso en situaciones especiales.Si por suerte aún tu consumo excesivo de sal no ha derivado en hipertensión, puedes prevenir esa y otras consecuencias para tu salud reduciendo su consumo. ¿Cómo?No añadas sal a las comidas.Retira el salero de la mesa.Evita los productos muy salados como apertivos, ahumados, salazones, encurtidos,…Reeduca a tu paladar.Quede claro y por delante que es el consumo habitual y en exceso el que genera el problema.FUENTE: https://elpais.com/salud-y-bienestar/2023-01-05/los-riesgos-del-consumo-excesivo-de-sal-hipertension-arterial-y-niveles-mas-altos-de-la-hormona-del-estres.html

Please join authors Loren Field and Sean Reuter, as well as Associate Editor Thomas Eschenhagen as they discuss the article "Cardiac Troponin I-Interacting Kinase Affects Cardiomyocyte S-Phase Activity But Not Cardiomyocyte Proliferation." Dr. Greg Hundley: Welcome listeners, to this January 10th issue of Circulation on the Run, and I am Dr. Greg Hundley, associate editor, director of the Pauley Heart Center at VCU Health in Richmond, Virginia. Dr. Peder Myhre: I am Dr. Peder Myhre from Akershus University Hospital and University of Oslo in Norway. Dr. Greg Hundley: Well, listeners, this week's feature discussion delves into the world of preclinical science and evaluates cardiac troponin I and its impact on S phase activity in cardiomyocytes, and does that relate to cardiomyocyte proliferation. But before we get to that, how about we grab a cup of coffee and Peder and I will work through some of the other articles in the issue. Peder, how about this week I go first? Dr. Peder Myhre: Go ahead, Greg. Dr. Greg Hundley: Right. So Peder, this first study evaluated whether the burden of positive coronary artery calcification on cardiovascular disease differed by multidimensional individual characteristics, and so the investigators led by Dr. Kosuke Inoue from Kyoto University sought to investigate the heterogeneity in the association between positive coronary artery calcium and incident cardiovascular disease. And so Peder, to examine this question, the authors implemented a cohort study design that included adults aged greater than 45 years, free of cardiovascular disease, from the Multi-Ethnic Study of Atherosclerosis, or MESA, and after propensity score matching in a one-to-one ratio, they applied a machine learning causal forest model to, first, evaluate the heterogeneity in the association between positive coronary artery calcium and incident cardiovascular disease and then, second, to predict the increase in cardiovascular disease risk at 10 years when the coronary artery calcium score was greater than zero, so versus is it zero at all at the individual level? Dr. Peder Myhre: Oh, Greg, that is so cool, so using machine learning for coronary artery calcium and risk prediction, I'm very excited. What did they find? Dr. Greg Hundley: Right, Peder, so the expected increases in cardiovascular disease risk when the coronary artery calcium score was greater than zero were heterogeneous across individuals. Moreover, nearly 70% of people with low atherosclerotic cardiovascular disease risk showed a large increase in cardiovascular disease risk when the coronary calcium score was greater than zero, highlighting the need for coronary artery calcium screening among such low-risk individuals. And Peder, future studies are really needed to assess whether targeting individuals for coronary artery calcium measurements based on not only the absolute ASCVD risk, but also the expected increase in CVD risk when a CAC score is greater than zero and whether that improves overall assessment of cardiovascular outcomes. Dr. Peder Myhre: Wow, that is so clinically relevant and very interesting. And we're actually going to stay clinically relevant with the next paper which is about anti-platelet therapy after PCI. And this paper describes the long-term results of the HOST-EXAM trial. To remind you, Greg, the HOST-EXAM trial was an investigator-initiated prospective, randomized, open label, multicenter trial done at 37 sites in Korea. They enrolled patients who had undergone PCI with DES and maintained dual anti-platelet therapy without any clinical event for a mean 12 months and then they were randomized one to-one to either clopidogrel, 75 milligrams once daily, or aspirin, 100 milligram once daily. The primary results of this trial was published in Lancet in 2021 and showed superiority of clopidogrel over aspirin in prevention of the composite of MACE and major bleeding during 24 months of followup. And then, through the current paper, this describes the results of the post trial extended followup of about five years. Dr. Greg Hundley: Very nice, Peder, so aspirin versus clopidogrel and looking at the maintenance of that monotherapy and cardiovascular outcomes. Wow, so what did they find? Dr. Peder Myhre: Yeah, Greg. They, in this extended followup study, had a total of 5.8 years median followup, and the primary endpoint occurred in 12.8% in the clopidogrel group versus 16.9% in the aspirin group, and that has a range of 0.74 with a 95% conference interval ranging from 0.63 to 0.86. So also the clopidogrel group had lower risk of the secondary thrombotic endpoint and the secondary bleeding endpoint while there was no significant difference in the incident on all caused death. So Greg, to conclude, these very interesting results from the primary analysis of the HOST-EXAM trial was consistent through the longer followup, and this support the use of clopidogrel over aspirin monotherapy from 12 months onwards after PCI. Dr. Greg Hundley: Very nice Peder, beautiful description and sounds like long-term clopidogrel use over aspirin was quite beneficial. Well, the next study comes to us from the world of preclinical science, and it is from the investigative group led by Dr. Yunzeng Zou from Shanghai Institute of Cardiovascular Diseases and the Zhongshan Hospital and Fudan University. Peder, the study pertains to diabetes. So diabetic heart dysfunction is a common complication of diabetes mellitus and cell death is a core event that leads to diabetic heart dysfunction. However, the time sequence of cell death pathways and the precise intervening time of particular cell death type remained largely unknown in diabetic hearts. And so, Peder, this study aimed to identify the particular cell death type that is responsible for diabetic heart dysfunction and propose a promising therapeutic strategy by intervening in this cell death pathway. Dr. Peder Myhre: Wow, Greg, that is really interesting. Heart dysfunction in diabetes is something that we really have to learn more about and I'm so excited to hear what these authors found, Greg. Dr. Greg Hundley: Right. So first, Peder, the authors identified necroptosis as the predominant cell death type at later stages in the diabetic heart. And then second, Peder, the CB2 receptor, and we'll call that CB2-R, recruits transcription factor Bach2 to repress necroptosis and protects against diabetic heart injury while hyperglycemia and MLKL in turn phosphorylates CB2-R to promote ubiquitous dependent degradation of CB2-R, thus forming a CB2-R centric feedback loop of necroptosis. And finally, Peder, cardiac CB2-R or Bach2 expression negatively correlates with both MLKL 10 expression and the extent of diabetic heart injuries in humans. And so the clinical implications of these findings, Peder, are that the CB2-R centric necrotic loop represents a promising target for the clinical treatment of diabetic heart injuries. Dr. Peder Myhre: So Greg, this paper that comes to us from corresponding author Amanda Paluch from University of Massachusetts Amherst, is a meta-analysis of eight prospective studies with device measured steps including more than 20,000 adults who were followed for CVD events. And the mean age of participants in this study was 63 years and 52% were women. And the participants were followed for a median of 6.2 years and 1,523 cardiovascular events occurred. So first, Greg, there was a significant difference in the association of steps per day in cardiovascular disease between older, that is greater or equal to 60 years, and younger, that is less than 60 years adults. So for older adults that has the ratio for cardiovascular disease using Q1 as reference was 0.80 for Q2, 0.62 for Q3, and 0.51 for Q4. And for younger adults that has ratio for cardiovascular disease using Q1 as reference was 0.79 for Q2, 0.90 for Q3, and 0.95 for Q4. And in the paper, Greg, there are some beautiful, restricted cubic lines that really illustrate the association between daily steps and the risk of cardiovascular disease among older adults and in younger adults. So the authors conclude that for older adults taking more daily steps is associated with a progressively lower risk of cardiovascular disease. And monitoring and promoting steps per day is a simple metric for clinician patient communication and population health to reduce the risk of cardiovascular disease. Dr. Greg Hundley: Well, Peder, we've got some other very interesting articles in this issue and how about we dive into that mail bag and discuss a few of those. So I'll go first. The first is a Perspective piece by Professor Powell-Wiley entitled “Centering Patient Voices through Community Engagement in Cardiovascular Research.” A very important topic where can those in the community actually help us design meaningful outcomes for our research initiatives? And next Peder, there is a Research Letter from Professor Evans entitled “Increasing Mononuclear deployed Cardiomyocytes by Loss of E2F7/8, and does that fail to improve cardiac regeneration post myocardial infarction?” Dr. Peder Myhre: Thanks, Greg. We also have an ECG Challenge by Dr. Li entitled, “What Is The Truth Behind Abnormal ECG Changes?” And this is describing a very rare and interesting cause of ST segment elevation. I recommend everyone to read that case. We also have our own Nick Murphy who gives us the Highlights from the Circulation Family of Journals where he summarizes five papers from the Circulation subspecialty journals. First, the experience with a novel visually assisted ablation catheter is reported in circulation A and E. The impact of various exercise training approaches on skeletal muscle in heart failure with preserved the F is presented in circulation heart failure. Gaps in heart failure treatment over a decade are reported in circulation cardiovascular quality and outcomes, and the associations of machine learning approaches to plaque morphology from coronary CTA with ischemia are reported in circulation cardiovascular imaging. And finally, Greg, an observational study of left main PCI at sites with and without surgical backup is reported in circulation cardiovascular interventions. Let's go on to the feature paper today describing the cardiac troponin I interacting kinase and the impact on cardiomyocyte S phase activity. Dr. Greg Hundley: Great, let's go. Welcome listeners to this January 10th feature discussion. Very interesting today as we are going to delve into the world of preclinical science. And we have with us today Dr. Loren Field and Dr. Sean Reuter from University of Indiana in Indianapolis, Indiana. And our own associate editor, Dr. Thomas Eschenhagen from University Medical Center of Hamburg in Hamburg, Germany. Welcome gentlemen. Well, Loren, we're going to start with you. Can you describe for us some of the background information that went into the preparation of your study, and what was the hypothesis that you wanted to address? Dr. Loren Field: Sure. This study actually came about in a rather roundabout fashion. We were doing a study with Kai Wollert in Hanover, Germany, where we were looking at the impact of a CXCR4 antagonist, which is used to mobilize stem cells from the bone marrow. And we had sent our mice over to Kai's lab and we have a mouse model that allows us to track S phase activity in cardiac myocytes, so these are cells are starting to replicate. And Kai crossed them into a different genetic background. And when he sent the mice back to us to analyze the hearts, we observed that we saw things that we never saw before in our experiments here. His injury model was different than ours and now the mouse also had a genetic background, so we had to spend about a year to figure out if it was the injury model or the background. It turned out to be the genetic background, and the phenotype was these mice had about a 15-fold elevated level of cell cycle reentry. So then it became a relatively simple genetics game where we took the progenitor mice, made F1 animals, looked for the phenotype, did backcross animals, and basically identified the gene responsible for the phenotype. Dr. Greg Hundley: Very nice. And so in this study moving forward, what hypothesis did you want to address? Dr. Loren Field: Well, the main hypothesis was to figure out what the gene was and then secondarily to figure out the degree of cell cycle progression. When the cell is proliferating, the first task is to replicate its genome, which is S phase activity that's followed by the nuclei dividing and then finally by the cell itself becoming two cells. So our task was to identify, first, the gene and secondly, how far through the cell cycles the cells progressed. Dr. Greg Hundley: Very nice. And how did you construct your experiment? Dr. Loren Field: It was, again, very straightforward. It was simply setting up the appropriate genetic crosses to produce the animals. For the past 10, 15 years, we've been developing a computer assisted assay that allows us to identify the anatomical position of S phase positive cardiac myocytes in sections of the heart. And basically, we apply that program to the different genetic backgrounds and after that it's a ball of mapping studies, QTL mapping. Dr. Greg Hundley: So really mechanistic understanding. Well listeners, we're next going to turn to Sean, and Sean, can you describe for us your study results? Dr. Sean Reuter: Yes, as Loren stated, we saw a 15-fold increase in the S phase activity within the remote zone. Now we partition the heart in three different zones after injury, so the scar, the border zone, and then the remote zone or injury. And as Loren stated, we saw a 15-fold increase in the S phase activity, cell cycle activity, in the remote zone. And it's only because we have this system in hand that we can anatomically map the S phase activity within the heart that we were able to detect and also quantify this. And I think that's the reason we discovered this particular phenotype. But in addition to that, we performed RNA-seq or Exome sequencing and discovered that TNNI3K was the responsible gene for elevated S phase activity within the remote zone and border zone, but interestingly not in the scar. Dr. Greg Hundley: Very interesting, Sean, and so describe for us the importance of the TNNI3K and its relationship to this S phase. Dr. Sean Reuter: Sure. This particular gene was first discovered around 2000, and it's been studied for a while now, but the targets of this kinase specifically expressed in the heart, and it does get elevated after injury, but the actual targets are not well described or well known. It's believed that it phosphorylates some mild filament fibers and structural proteins, but the actual mechanism and the consequence of this is not known. So when we saw this in the remote zone, the elevated S phase, our current theory is that we believe that it's probably increasing oxidative stress that would basically further out from the at-risk zone or the border zone and then it now is in the remote zone. So we think it's just causing the heart, a pathological area of the heart, basically to expand. And so that's our current theory. Other groups have published on the oxidative stress in over expression of TNNI3K as well. Dr. Greg Hundley: Very nice. Well listeners, next we are going to turn to our associate editor, Thomas many articles come your way and come across your desk. What attracted you to this particular article, and how do we put its results really in the context of cardiac regeneration? Dr. Thomas Eschenhagen: Indeed, there were several arguments. It's a cool paper and the whole field is still very important. As probably most of you know, the field have a rough ride over the last 20 years, went up and down, lots of bad findings. And in the end it turns out that we are there where we have been 20 years ago, the mammalian heart essentially doesn't regenerate. So anything which would improve that would be of very major importance. Why is it a good paper? Because it starts from a very clear finding, one mouse, which looks like strongly regenerating after MI, another mouse line, which doesn't. And so by applying, let's say, classical genetic, very stringent methodology, Loren Field and his group identified this troponin I kinase to be the culprit. And they also proved it, because putting it back in the strain with a low, so-called, regeneration brought it back to the other level. So it's a very clear, nice methodology. And finally, it's also a bit provocative because others in a very prominent paper, actually, have shown that this kinase... Or they concluded more or less just the opposite. The reason for the discrepancy is not quite clear and I was very happy to learn that the two groups actually discussed about it. So it's not just a bad controversy, but something which brings forward science. And finally, I think something we didn't talk about yet today, what I particularly liked, maybe the most, on this paper is that this group didn't stop at the point of DNA synthesis. Everybody else would've probably said, "Okay, here we are, one regenerate the other doesn't." But in the very important extra finding of this paper is that this is just increased DNA synthesis and not more myocytes. And this distinction is so critical to the field because people forget that adult mammalian cardiomyocytes often have several nuclei and individual nuclei have more than one set of chromosomes, so this polyploid. And so if you see DNA synthesis like in this paper, it doesn't necessarily mean more myocytes. And actually here it was shown that it is not more myocytes but more polyploidization and making this difference so clear, I think it's a very important contribution to the field. Dr. Greg Hundley: Very nice. Well, listeners, we're going to turn back to each of our guests today and we'll start with you Loren. Based on your results, what do you see as the next study moving forward in this sphere of research? Dr. Loren Field: I think these results made me appreciate for the first time that the intrinsic level of cell cycle reentry, that's just the S phase, not the cell division, is actually much higher than I had thought previously. And this was because we just fortuitously, or I guess anti-fortuitously, we're using a strain that had low levels of S phase induction. If you calculate the turnover, if every nucleus that it synthesized DNA actually went on to have that cell divide, you could replace a 50% loss of myocytes over the course of about 550 days, give or take. And to me, that's actually telling me that if we could push those cells from just being polypoid, as Thomas was saying, to actually go through cytokinesis, there would be enough intrinsic activity to go forward. So this really tells me that what we should be focusing on is now not trying to induce cell cycle, but to allow the cells that are entering the cell cycle to actually progress through it. Dr. Greg Hundley: Very nice. And Sean? Dr. Sean Reuter: Yes, well, echoing Loren's point there, it's really not necessarily cell cycle induction, it's cell cycle completion to the cytokinetic fate. And that's the key. If we can get to that point, if we can figure out the mechanism to get to that point, then we have a wonderful discovery. However, we're not quite there yet, but we hope to be. Dr. Greg Hundley: And Thomas. Dr. Thomas Eschenhagen: Well, nothing to add really from my side, except that I would like to know what this Troponin I kinase does, because that is somehow still a missing link. How does this kinase lead to more DNA synthesis or the initiation of cell cycling? That would be an important finding and I'm sure there will be more research going on. Particularly also, to solve this discrepancy, I mean, there must be something in it and we don't quite yet know how, but I think we are in a good way. I'm sure there will be papers showing that soon. So I think that's, again, a very good start for this discussion. Dr. Greg Hundley: Well, listeners, we want to thank Dr. Loren Field, Dr. Sean Reuter and Dr. Thomas Eschenhagen for bringing us this really informative study in mammalian myocellular regeneration, highlighting that the level of cardiomyocyte cell cycle reentry in hearts expressing TNNI3 kinase would lead to significant regenerative growth if each cardiomyocyte exhibiting S phase activity was able to progress through cytokinesis. And this in turn suggests that identification of factors which facilitate cardiomyocyte cell cycle progression beyond S phase will be key to unlocking the intrinsic regenerative capacity of the heart. Well, on behalf of Carolyn, Peder and myself, we want to wish you a great week and we will catch you next week on the run. This program is copyright of the American Heart Association 2023. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, please visit ahajournals.org.

Rob Hegele is Distinguished University Professor of Medicine and Biochemistry, Western University, and Director of London Regional Genomics Centre at Robarts Research Institute. He holds the Jacob J. Wolfe Distinguished Medical Research Chair in Human Gene Function, and the Martha G. Blackburn Chair in Cardiovascular Research. He cares for > 2400 patients in his lipid clinic at University Hospital. He was among the first in North America to use 5 experimental medications, of which 4 are now available for prescription (rosuvastatin, sitagliptin, lomitapide and evolocumab) to treat high cholesterol or diabetes. In addition, his patients have been among the first in Canada to use mipomersen, anacetrapib, bococizumab, evinacumab, volanesorsen, and inclisiran. His laboratory, alone or in collaboration, discovered the molecular genetic basis of 25 human diseases. He has published > 815 papers, which have been cited > 60,000 times in the medical literature. He is listed in the ISI database of the top 1% of highly cited scientists in the world. In 2021, the website “Expertscape.com” ranked him #1 globally in the area of “hypertriglyceridemia” and #2 for “disorders of lipid metabolism.” He has co-authored many clinical practice guidelines for cholesterol, blood pressure and diabetes, and has contributed to international guidelines on familial hypercholesterolemia and hypertriglyceridemia. He has trained numerous physicians, medical students and graduate students. Purchase Tommy's MetFlex-Rx Diet Book: https://amzn.to/2ZUeMBm Purchase Tommy's Behaviour Change Book on Audible: https://amzn.to/3IjqEOJ Dr.Appleton's Website: https://andrewappletonmd.ca/

Robb MacLellan, MD is the Director of the UW Medicine Heart Institute and our Division Head of Cardiology.   Since 2011 he has ensured our faculty and research goals are aligned with the needs and opportunities in the hospital.  In addition to those important responsibilities, he is an active attending physician and Robert A. Bruce Endowed Chair in Cardiovascular Research.Robb's research interests include:Understand the molecular mechanisms that regulate cardiac failure and develop therapies to regenerate myocardiumUse genetic mouse models in an attempt to correlate molecular insights with whole organ physiologyDevelop stem cell and tissue engineering strategies to repair the heart1:15 - The Canadian Researcher6:00 - Why Cardiology7:27 - Research Training10:45 - Research Fundamentals13:15 - First Trial to the Lab Today26:40 - Complimentary Teamwork Success30:55 - Advice to the Future Academic35:50 - The Argument for the Physician Scientist41:20 - Struggle for Balance in Training and Future Need46:55 - Looking back as Division Head and Director52:30 - Regional Heart Center to Heart Institute56:30 - A new role in Department of Medicine

Eating a high-salt diet, like most Americans do, appears to increase stress. In a new study published in the journal Cardiovascular Research, researchers at the University of Edinburgh in Scotland looked at the effects of high salt consumption on stress and the brain in mice. They observed that eating a large amount of salt-rich food […] The post 332. Eating salt-rich foods might increase stress levels appeared first on Dr. David Geier - Feel and Perform Better Than Ever.

Listen to today's 7-minute Live from the American Heart Association Conference as Dr. Koren tells us what's new in heart health.  Join Dr. Michael Koren and Kevin Geddings each Monday as they give you the quick down-and-dirty truth behind the most recent medical data.  Dr. Michael Koren is a practicing cardiologist and CEO at ENCORE Research Group. He has been the principal investigator of 2000+ clinical trials while being published in the most prestigious medical journals.  Dr. Koren received his medical degree cum laude at Harvard Medical School and completed his residency in internal medicine with a fellowship in cardiology at New York Hospital/Memorial Sloan-Kettering Cancer Center/Cornell Medical Center.  On a personal note, Dr. Koren has a life-long interest in history, technology, Public Health, and music. He has written two musical plays.More information and to Participate in Clinical Research Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow MedEvidence! on Social Media to discover the Truth Behind the Data.FacebookInstagramTwitterLinkedInPowered by ENCORE Research Group at www.ENCOREDOCS.comOriginal Air Date: November 7, 2022#MedEvidence #heart #americanheartassociation #cardiohealth #cardiovasularresearch #LPa #hearthealth #clinicalresearch #clinicaltrials

即刻加入15Mins通勤學英語直播室，每週一9pm等你來說英文 : https://15minsengcafe.pse.is/46hm8k 每日英語跟讀 Ep.K440: How to Get Heart Patients to Take Their Pills? Give Them Just One. Heart disease kills more people than any other condition, but despite advances in treatment and prevention, patients often do not stick to their medication regimens. Now researchers may have found a solution: a so-called polypill that combines three drugs needed to prevent cardiovascular trouble. 死於心臟病的人比死於其他任何疾病的人都多，儘管在治療和預防上取得進展，患者往往不能堅守他們的藥物治療方式。現在，研究人員可能已經找到一個解決方法：一種混合三種預防心血管疾病所需藥物的所謂複方製劑。 In what is apparently the largest and longest randomized controlled trial of this approach, patients who were prescribed a polypill within six months of a heart attack were more likely to keep taking their drugs and had significantly fewer cardiovascular events, compared with those receiving the usual assortment of pills. 在明顯是這種方法規模最大、時間最長的隨機對照試驗中，心臟病發作後6個月內服用複方製劑的患者，跟服用常規藥物患者相比，更有可能繼續服用藥物，心血管事件明顯減少。 The participants also experienced one-third fewer cardiovascular deaths, although their overall risk of death from all causes was not significantly changed. 參與者因心血管疾病死亡人數也減少三分之一，即便他們因為各種原因死亡的總體風險沒有顯著改變。 The study of more than 2,000 heart patients, who were followed for three years, was published Friday morning in The New England Journal of Medicine, as the findings were presented at the European Society of Cardiology Congress in Barcelona, Spain. 這項研究對2000多名心臟病患者進行三年追蹤調查，研究結果周五上午發表在《新英格蘭醫學雜誌》，並在西班牙巴塞隆納舉行的歐洲心臟病學會年會上發表。 The study is the culmination of 15 years of work by researchers led by Dr. Valentin Fuster, director of Mount Sinai Heart at Mount Sinai Hospital in New York City and general director of the National Center for Cardiovascular Research in Spain. 這研究是紐約市西奈山醫院西奈山心臟中心主任、西班牙國立心血管研究中心總監瓦倫丁．福斯特博士帶領研究人員研究15年的結晶。 “Combination pills are easier for the physician and for the patient, and the data are pretty clear — it translates into a benefit,” said Dr. Thomas J. Wang, chair of the department of internal medicine at UT Southwestern Medical Center, who was not involved in the research but wrote an editorial accompanying the study. 未參與研究但為研究報告撰寫社評的德州大學西南醫學中心內科系主任湯瑪斯．王博士說：「複方藥物對醫生和病患來說更簡便，數據非常清楚，它轉化為一種好處。」 The polypill combines a blood-pressure medication, a cholesterol-lowering drug and aspirin, which helps prevent blood clots. 這種複方製劑結合了降壓藥、降膽固醇藥和阿斯匹林，有助防止血栓。 The polypill used in the study has not been approved by the Food and Drug Administration and is not available to patients in the United States right now. Fuster said the results of the new trial would be submitted to the agency shortly in an effort to obtain approval. 這項研究使用的複方製劑還未獲得美國食品藥物管理局批准，目前在美國還不能給患者使用。福斯特 說，這項新試驗結果很快會提交給該機構，以爭取獲得批准。 And since participants became even more likely to keep taking the polypill over time, he said, “The potential results could be even better with more follow-up.” Several studies have shown that only about half of patients, or even less, take all their medications as instructed. 他說，由於參與者會逐漸的更可能繼續服用複方製劑，「若有更多後續研究，潛在結果可能更好」。數項研究顯示，只有大約一半甚至更少患者按照指示服用所有藥物。 The new study, a randomized controlled clinical trial, enrolled just under 2,500 patients at 113 sites in Spain, Italy, France, Germany, Poland, the Czech Republic and Hungary. 這項研究是一項隨機對照臨床試驗，在西班牙、義大利、法國、德國、波蘭、捷克和匈牙利的113個地點招募到近2500名患者。Source article: https://udn.com/news/story/6904/6601708 歡迎留言告訴我們你對這一集的想法： https://open.firstory.me/user/cl81kivnk00dn01wffhwxdg2s/comments Powered by Firstory Hosting

How do the 3 Rs of Research – Refinement, Reduction, Replacement – factor into a methodological paper regarding a novel quantitative method for using an electrocardiogram to determine which animals have infarcts that reflect successful coronary ligation? Listen as Consulting Editor Dr. Ganesh Halade (University of South Florida) interviews lead author and Consulting Editor Dr. Kristine DeLeon-Pennell (Medical University of South Carolina) and content expert Dr. Corey Reynolds (Merck) about the recent work by Broughton et al. What started as an internal project to improve The DeLeon-Pennell Lab's surgical success grew into a research article published as part of a Call for Papers on Innovation in Improving Rigor and Reproducibility in Cardiovascular Research. The DeLeon-Pennell Lab was interested in streamlining infarct size between lab members, students, and technicians during the surgical procedures used for their mouse studies. Aiming for a threshold of 35% infarct size, the DeLeon-Pennell Lab wanted to move beyond looking only at the elevation of the T wave to confirm infarct size. To do so, Broughton et al. designed a new ECG method that provides real-time feedback during the procedure. Broughton et al. found that area under the QRS curve is stronger for predicting successful MI surgeries with an infarct size greater than 35%. This new method will ultimately allow researchers to reduce the time spent performing surgical experiments and the overall number of animals used. Listen now to find out more.   Philip Broughton, Miguel Troncoso, Alexa Corker, Alexus Williams, Dawson Bolus, Gualberto Munoz, Caroline McWhorter, Hallie Roerden, Penny Huebsch, and Kristine Y. DeLeon-Pennell Riding the wave: a quantitative report of electrocardiogram utilization for myocardial infarction confirmation Am J Physiol Heart Circ Physiol, published August 3, 2022. DOI: doi.org/10.1152/ajpheart.00201.2022

Dr. Uwe Schoenbeck, Ph.D., (https://www.pfizer.com/research/science_and_technology/meet_our_scientists/uwe_schoenbeck) is Chief Scientific Officer, Emerging Science & Innovation (ES&I) and Senior Vice President, Worldwide Research and Development & Medical (WRDM) at Pfizer. Part of Worldwide Research, Development & Medical, ES&I is charged with enhancing Pfizer's pipeline through translation of external emerging science into breakthrough therapies for patients and through dedicated outreach to academia, consortia and biotech. Through its Emerging Science Liaisons located around the globe, they work across Pfizer's Therapeutic Areas to harness external cutting edge pre-clinical assets and breakthrough technologies applying a broad range of partnering vehicles, including research collaborations, consortia, licensing, and acquisitions. ES&I also engages in equity investments as well as seed investments and formation of new companies. It has a Target Sciences team which is focused on novel target and biology discovery research to introduce differentiated First-in-Class programs with enhanced confidence in rationale into the WRDM portfolio. And through its new Centers for Therapeutic Innovation (CTI - https://www.pfizercti.com/), ES&I prosecutes cutting edge science sourced from leading academic and medical centers globally, working in close partnership with external PIs and building an exciting pipeline across the range of Pfizer's core areas. Dr. Schoenbeck brings fifteen years of pharmaceutical drug development experience to Pfizer's R&D executive leadership team. Prior to joining the company, he served as Vice President, Emerging R&D Innovation for Wyeth and Vice President, Cardiovascular Research for Boehringer Ingelheim. Before joining industry, he held an Assistant Professor of Medicine position at Brigham & Women's Hospital, Harvard Medical School. He has served as a reviewer for multiple peer-reviewed journals and has published more than 100 peer-reviewed articles, review articles, book chapters and abstracts with particular contributions in molecular and cell biology, cardiovascular research, immunology and metabolism. Dr. Schoenbeck earned his Ph.D. from the University of Kiel, Germany, and completed postdoctoral training in the Division of Cardiovascular Medicine, Brigham & Women's Hospital, Harvard Medical School, before joining as a faculty member.

Commentary by Dr. Valentin Fuster

Many environmental factors have been found to influence cardiovascular disease (CVD) risk, progression, and severity. Join Sanjay Rajagopalan, MD, FACC, FAHA, Chief of Cardiovascular Medicine at the University Hospitals, Harrington Heart & Vascular Institute, Director of Cardiovascular Research Institute at Herman K. Hellerstein MD, Professor of Cardiovascular Research, and Professor of the Department of Internal Medicine at Case Western Reserve University, as he is interviewed by Betul Hatipoglu MD, Professor of Medicine at CWRU School of Medicine, Vice-Chair at UH System Clinical Affairs, Department of Medicine, Medical Director of the Diabetes & Obesity Center at Mary B. Lee Chair in Adult Endocrinology, University Hospital Cleveland Medical Center, and Chair of the AACE Disease State Network Lipids & Cardiovascular Health. Dr. Rajagopalan and Dr. Hatipoglu discuss components of the environment that play an important role in health besides general lifestyle factors, including social, economic, and chemical pollutants.

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-271 Overview: Given the prevalence of cardiovascular disease (CVD) in the United States, it is key for primary care providers to counsel patients on the importance of exercise for CVD prevention. This brief podcast explores data that will help clinicians understand the need to prescribe exercise and rehabilitation in the primary care setting. You'll walk away with clear guidance to offer patients and ultimately improve outcomes in CVD as well as multiple chronic diseases. Episode resource links: Naci, H., & Ioannidis, J. P. (2015). Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. British journal of sports medicine, 49(21), 1414–1422. https://doi.org/10.1136/bjsports-2015-f5577rep   Sanchis-Gomar, F., Lavie, C. J., Marín, J., Perez-Quilis, C., Eijsvogels, T. M., O'Keefe, J. H., ... & Blair, S. N. (2021). Exercise effects on cardiovascular disease: from basic aspects to clinical evidence. Cardiovascular Research.  Guest: Mariyan L. Montaque, DNP, FNP-BC   Music Credit: Richard Onorato

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-271 Overview: Given the prevalence of cardiovascular disease (CVD) in the United States, it is key for primary care providers to counsel patients on the importance of exercise for CVD prevention. This brief podcast explores data that will help clinicians understand the need to prescribe exercise and rehabilitation in the primary care setting. You'll walk away with clear guidance to offer patients and ultimately improve outcomes in CVD as well as multiple chronic diseases. Episode resource links: Naci, H., & Ioannidis, J. P. (2015). Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. British journal of sports medicine, 49(21), 1414–1422. https://doi.org/10.1136/bjsports-2015-f5577rep   Sanchis-Gomar, F., Lavie, C. J., Marín, J., Perez-Quilis, C., Eijsvogels, T. M., O'Keefe, J. H., ... & Blair, S. N. (2021). Exercise effects on cardiovascular disease: from basic aspects to clinical evidence. Cardiovascular Research.  Guest: Mariyan L. Montaque, DNP, FNP-BC   Music Credit: Richard Onorato

Despite the establishment of NIH guidelines for inclusion of women in clinical studies, as well as clear expectations for rigor and reproducibility in reporting sex as a biological variable in NIH grant submissions, women and females are still understudied populations in human and animal research. Enter this important primer on incorporating sex as a biological variable into basic and clinical research. Listen as Consulting Editor Austin Robinson, PhD (Assistant Professor, Neurovascular Physiology Laboratory, Auburn University) interviews lead author Quin Denfeld, PhD, RN (Assistant Professor, School of Nursing and Division of Cardiovascular Medicine, School of Medicine, Oregon Health & Science University) and women's health expert Judith Regensteiner, PhD (Director of the Ludeman Family Center for Women's Health Research and Professor of Medicine, Divisions of Internal Medicine and Cardiology, University of Colorado Anschutz Medical Campus).  Denfeld and co-authors heeded the call to action outlined in the recent editorial by the AJP-Heart and Circ Editors on “Reinforcing rigor and reproducibility expectations for use of sex and gender in cardiovascular research”, along with its accompanying podcast episode and Call for Papers on Considering Sex as a Biological Variable in Cardiovascular Research.    In their Perspective article, Denfeld et al. offered practical and actionable ideas for how to include women and females in research studies, demystifying the process for fellow researchers by addressing common concerns such as sample size, cost, statistical analysis, and study participant recruitment challenges. In this episode, our experts tackled these subjects head on, championing the value of looking at data, even pilot data, through the lens of sex differences.   Don't miss hearing about career development opportunities available to researchers from the NIH Office of Research on Women's Health and Building Interdisciplinary Research Careers in Women's Health (BIRCWH) Program.  Including both sexes and genders in research studies is not difficult to accomplish with foresight, planning, and perhaps a little creative thinking. This insightful conversation is invaluable to all researchers. Listen now.   Recommended Reading in AJP-Heart and Circ: Quin E. Denfeld, Christopher S. Lee, and Beth A. Habecker  A primer on incorporating sex as a biological variable into the conduct and reporting of basic and clinical research studies Am J Physiol Heart Circ Physiol, published February 8, 2022. DOI: 10.1152/ajpheart.00605.2021   Austin T. Robinson, Megan M. Wenner, Kanokwan Bunsawat, Joseph C. Watso, Gabrielle E. W. Giersch, and Nisha Charkoudian When it's time for the sex talk, words matter  Am J Physiol Heart Circ Physiol, published December 13, 2021. DOI: 10.1152/ajpheart.00556.2021   Special Article Collection on Considering Sex as a Biological Variable  

The papers behind the pod: 1. Baran SW et al. (2022). Perspectives on the Evaluation and Adoption of Complex In Vitro Models in Drug Development: Workshop with the FDA and the Pharmaceutical Industry (IQ MPS Affiliate). ALTEX, in press. https://doi.org/10.14573/altex.21122032. Borba JVB et al. (2022) STopTox: An in Silico Alternative to Animal Testing for Acute Systemic and Topical Toxicity. Environmental Health Perspectives 130(2). https://doi.org/10.1289/EHP93413. van der Velden J et al. (2022) Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC working group on myocardial function and the ESC Working Group on Cellular Biology of the Heart. Cardiovascular Research, in press. https://doi.org/10.1093/cvr/cvab370 It's the third Thursday of March, and you're listening to 3 Minute 3Rs, your monthly recap of efforts to replace, reduce and refine the use of animals in research. This month, we're highlighting three papers focusing on replacement. Follow this link for the full transcript: https://nc3rs.org.uk/3-minute-3rs-podcast-march-2022-transcript See acast.com/privacy for privacy and opt-out information.

Our inaugural podcast is a discussion between Dr. Paul Thompson, Chief of Cardiology, Emeritus, at Hartford Hospital and Professor of Medicine, Emeritus, at University of Connecticut and Dr. Thomas Nero, Director of Cardiovascular Research at CAFC about coronary artery disease, lipid sub-fractionation and the role of lipoprotein a, aka Lp(a).

Tierversuche erhitzen die Gemüter. Ohne geht es nicht, sagen weite Teile der Forschung. Tierschützer halten entgegen, dass es bereits erprobte Alternativmethoden gibt. Aber wie gut sind die wirklich? In welchen Bereichen können zum Beispiel Organoide die Zahl der Versuchstiere spürbar senken und Tierleid vermeiden helfen? Unsere Autorin Nele Rößler hat sich erklären lassen, wie künstliche Herzmuskel hergestellt werden und wo ihre Grenzen liegen. Im Gespräch mit Host Lucie Kluth erläutert sie, was auf einem Chip nachgestellte Mini-Organe leisten und warum es so schwer ist, in der Medikamentenentwicklung auf Versuche am lebenden Organismus zu verzichten. Außerdem nimmt sie uns mit ins Labor Hamburger Biologinnen, die sich mit Einsatzmöglichkeiten für Schlachtabfälle beschäftigen - und dabei erstmal rausfinden müssen, mit welcher Maschine sich Schweinenieren möglichst dünn und schonend schneiden lassen. Eine Recherche, die Hoffnung macht - und doch zu große Erwartungen dämpft. Mit dieser Episode knüpfen wir an unsere Podcast-Folge 38 an, "Vom Wert der Tiere". DIe Hintergrundinformationen • NDR Synapsen: Vom Wert der Tiere https://www.ndr.de/podcastsynapsen204.html • Video eines Herz-Organoids | Institut für Molekulare Biotechnologie der Österreichischen Akademie der Wissenschaften: Pulsierende Herzen in der Petrischale, Mai 2021 https://www.oeaw.ac.at/imba-de/ueber-imba/newsroom/news/pulsierende-herzen-in-der-petrischale • Leitfaden zur Reduzierung von Versuchstieren in der kardiovaskulären Forschung | Van der Velden et al: Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart in Cardiovascular Research 2022 https://academic.oup.com/cardiovascres/advance-article/doi/10.1093/cvr/cvab370/6499268?login=true • TED-Talk zur Organ-on-a-Chip-Technologie | Geraldine Hamilton: Körperteile auf Chips, Dezember 2013 https://www.youtube.com/watch?v=CpkXmtJOH84 • Verringert die Organ-on-a-Chip-Methode die Anzahl von Tierversuchen? | Christine Broll, Wenn das Plättchen im Herzschlag pulsiert, Fraunhofer-Magazin, März 2019 https://www.fraunhofer.de/de/forschung/aktuelles-aus-der-forschung/biooekonomie/gesundheit/organs-on-a-chip.html • Reduktion von Tierversuchen in der experimentellen Arzneimittelprüfung | Bundesgesundheitsblatt- Gesundheitsforschung - Gesundheitsschutz, Behrensdorf-Nicol und Krämer, September 2014 https://www.pei.de/SharedDocs/Downloads/wiss-publikationen-volltext/bundesgesundheitsblatt/2014/2014-reduktion-tierversuche-exp-arzneimittelpruefung.pdf?__blob=publicationFile&v=2

Tierversuche erhitzen die Gemüter. Ohne geht es nicht, sagen weite Teile der Forschung. Tierschützer halten entgegen, dass es bereits erprobte Alternativmethoden gibt. Aber wie gut sind die wirklich? In welchen Bereichen können zum Beispiel Organoide die Zahl der Versuchstiere spürbar senken und Tierleid vermeiden helfen? Unsere Autorin Nele Rößler hat sich erklären lassen, wie künstliche Herzmuskel hergestellt werden und wo ihre Grenzen liegen. Im Gespräch mit Host Lucie Kluth erläutert sie, was auf einem Chip nachgestellte Mini-Organe leisten und warum es so schwer ist, in der Medikamentenentwicklung auf Versuche am lebenden Organismus zu verzichten. Außerdem nimmt sie uns mit ins Labor Hamburger Biologinnen, die sich mit Einsatzmöglichkeiten für Schlachtabfälle beschäftigen - und dabei erstmal rausfinden müssen, mit welcher Maschine sich Schweinenieren möglichst dünn und schonend schneiden lassen. Eine Recherche, die Hoffnung macht - und doch zu große Erwartungen dämpft. Mit dieser Episode knüpfen wir an unsere Podcast-Folge 38 an, "Vom Wert der Tiere". DIe Hintergrundinformationen • NDR Synapsen: Vom Wert der Tiere https://www.ndr.de/podcastsynapsen204.html • Video eines Herz-Organoids | Institut für Molekulare Biotechnologie der Österreichischen Akademie der Wissenschaften: Pulsierende Herzen in der Petrischale, Mai 2021 https://www.oeaw.ac.at/imba-de/ueber-imba/newsroom/news/pulsierende-herzen-in-der-petrischale • Leitfaden zur Reduzierung von Versuchstieren in der kardiovaskulären Forschung | Van der Velden et al: Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart in Cardiovascular Research 2022 https://academic.oup.com/cardiovascres/advance-article/doi/10.1093/cvr/cvab370/6499268?login=true • TED-Talk zur Organ-on-a-Chip-Technologie | Geraldine Hamilton: Körperteile auf Chips, Dezember 2013 https://www.youtube.com/watch?v=CpkXmtJOH84 • Verringert die Organ-on-a-Chip-Methode die Anzahl von Tierversuchen? | Christine Broll, Wenn das Plättchen im Herzschlag pulsiert, Fraunhofer-Magazin, März 2019 https://www.fraunhofer.de/de/forschung/aktuelles-aus-der-forschung/biooekonomie/gesundheit/organs-on-a-chip.html • Reduktion von Tierversuchen in der experimentellen Arzneimittelprüfung | Bundesgesundheitsblatt- Gesundheitsforschung - Gesundheitsschutz, Behrensdorf-Nicol und Krämer, September 2014 https://www.pei.de/SharedDocs/Downloads/wiss-publikationen-volltext/bundesgesundheitsblatt/2014/2014-reduktion-tierversuche-exp-arzneimittelpruefung.pdf?__blob=publicationFile&v=2

Host: Kathryn MacKay Guest: Lida Sarafraz, University of Utah Paper: Understanding and Correcting Sex Disparity in Cardiovascular Disease Research: Ethical and Practical Solutions Transcript: provided by Otter.ai Music: The City Sleeps by Death by Ginger

"Everyone wants to be on the winning team." - Tim Fischell‍Dr. Tim Fischell is a Professor of medicine at Michigan State University and Medical Director of the Department of Cardiovascular Research, as well as Director of the Interventional Cardiology fellowship program at the Borgess Heart Institute in Kalamazoo, Michigan. He has an active practice as an interventional cardiologist at the Borgess Heart Institute in Kalamazoo. After receiving his medical degree from Cornell University Medical Center, Dr. Fischell completed an internship and residency in internal medicine at Massachusetts General Hospital at Harvard University and then completed his cardiology fellowship and interventional cardiology fellowship at Stanford University Medical Center. He was on the faculty at Stanford for five years, and then director of the cardiac cath labs and interventional cardiology at Vanderbilt University from 1992 to 1996. Dr. Fischell is board certified in internal medicine, cardiovascular medicine, and interventional cardiology. Dr. Fischell is an active inventor with more than 100 issued US patents. He has served as principal investigator for five National Institutes of Health grants, as well as several other research grants. Dr. Fischell has research interests in vascular biology, interventional cardiology devices,  such as stents, and renal denervation, and has presented more than 200 papers in the United States and abroad. A member of the editorial board, of Cardiovascular  Revascularization Medicine,  Journal of Invasive Cardiology, and the Journal of Interventional Carademydiology. Dr. Fischell has authored more than 120 papers. He is a founder and a CMO of Ablative Solutions and CEO and Co-founder of CrossLiner Inc., And is a serial entrepreneur and founder of eight other medical device companies. He has received numerous awards and honors, including the Thorax Center Andrius Gruntzig Award for the inventor of the year in 1997, the CRT 2015 Innovation Award, and is a fellow in the National Academy of Inventors.Please enjoy!‍Click here to subscribe to The Sell My Business Podcast to save time and effort. SELECTED LINKS FOR THIS EPISODEDr. Tim Fischell on LinkedInThe Deep Wealth ExperienceBook Your FREE Deep Wealth Strategy Call This podcast is brought to you by Deep Wealth. Your liquidity event is the most important financial transaction of your life. You have one chance to get it right, and you better make it count. But unfortunately, up to 90% of liquidity events fail. Think about all that time, money and effort wasted. Of the "successful" liquidity events, most business owners leave 50% to over 100% of their deal value in the buyer's pocket and don't even know it.Our founders said "no" to a 7-figure offer and "yes" to a 9-figure offer less than two years later. Don't become a statistic and make the fatal mistake of believing that the skills that built your business are the same ones for your liquidity event. After all, how can you master something you've never done before? Are you leaving millions on the table? Learn how the 90-day Deep Wealth Experience and our 9-step roadmap helps you capture the maximum value for your liquidity event.  ‍Click here to book your free exploratory strategy session.‍Enjoy the interview!

On today's epsiode, Dr. Jaime has a real "Salty" conversation with Dr. James DiNicolantonio. Dr. DiNicolantonio, is a Doctor of Pharmacy and a cardiovascular research scientist. A well-respected and internationally known scientist and an expert on health and nutrition, he has contributed extensively to health policy and has testified in front of the Canadian Senate regarding the harms of added sugars. He serves as the associate editor of the British Medical Journal's Open Heart, a journal published in partnership with the British Cardiovascular Society, and is on the editorial advisory boards of several other medical journals. Dr. DiNicolantonio is the author or coauthor of over 250 publications in the medical literature. He also is the author of five bestselling health books, The Salt Fix, Superfuel, The Longevity Solution, The Immunity Fix and The Mineral Fix. You can follow him on Instagram and Twitter @drjamesdinic and on Facebook at Dr. James DiNicolantonio. You can visit his website at drjamesdinic.com

Dr. Jeffrey Berger is an Associate Professor of Medicine and Surgery (on tenure track) with appointments in Cardiology, Hematology, and Vascular Surgery, and Director of Cardiovascular Thrombosis at New York University School of Medicine. During his training, he received a Master's degree in clinical research from the NIH K30 program at Albert Einstein College of Medicine. He completed fellowships in Cardiology at Duke University, Cardiovascular Research training at Duke Clinical Research Institute, and Vascular Medicine and Thrombosis and Hemostasis at the University of Pennsylvania. Dr. Berger has been the recipient of several grants, honors and awards, including the American Heart Association's Fellow Faculty award, amongst many others. He has also established an independent NIH-funded research program, investigating the role of platelet activity and thrombotic biomarkers in cardiovascular disease. How can we develop a more positive environment in medicine? For starters, says Dr. Jeffrey Berger, is finding ways to bring out the best in those around us. On top of that, Dr. Berger believes hard work, perseverance, and curiosity are the key principles for success. Today, he teaches us how to construct the mindset we need to persevere in medicine—and how to help others succeed along the way, too. Pearls of Wisdom: 1. Ask yourself the questions you want to answer and do not pursue meaningless paths in life. Ask yourself how you can make fresh contributions to your field that few others are making. 2. Be different. Do not conform to a specific mold but be willing to go places, do stuff, and try things others might not attempt. 3. Create an environment of encouragement. Do your best to bring out the best in those around you. 4. Persevere through difficult seasons. Be curious and willing to try hard, fail, and then try again.